BAGEL, J.; ARMSTRONG, A. .; WARREN, R.; PAPP, K.; THAÇI, D.; MENTER, A.; CATHER, J.; AUGUSTIN, M.; HIPPELI, L.; DAAMEN, C.; GRIFFITHS, C. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s47, 2022. DOI: 10.25251/skin.6.supp.47. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1802. Acesso em: 3 jul. 2024.